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Abstract
The Bayesian approach has become increasingly popular because it allows to model
quite complex models via Markov chain Monte Carlo (MCMC) sampling. However, it is
also recognized nowadays that MCMC sampling can become computationally prohibitive
when a complex model needs to be fit to a large data set. To overcome this problem,
we applied and extended a recently proposed two-stage approach to model a complex
hierarchical data structure of glaucoma patients who participate in an ongoing Dutch
study. Glaucoma is one of the leading causes of blindness in the world. In order to detect
deterioration at an early stage, a model for predicting visual fields (VF) in time is needed.
Hence, the true underlying VF progression can be determined, and treatment strategies
can then be optimized to prevent further VF loss. Since we were unable to fit these data
with the classical one-stage approach upon which the current popular Bayesian software
is based, we made use of the two-stage Bayesian approach. The considered hierarchical
longitudinal model involves estimating a large number of random effects and deals with
censoring and high measurement variability. In addition, we extended the approach with
tools for model evaluation
KEY WORDS: Bayesian modeling, Hierarchical structure, Longitudinal data analysis,
Two-stage approach.
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1 Introduction
Since the introduction of MCMC sampling by Gelfand and Smith [8] and the development
of the BUGS software [19] the Bayesian approach has become tremendously popular in
various application areas, but especially to fit models to complex data structures. But
with the years it also became clear that MCMC sampling can be computationally quite
cumbersome, and even prohibitive, for fitting complex models to relatively large data sets.
Several attempts have been made to look for alternative computational procedures and
software, with notable examples such as INLA [24] and STAN [11]. While this newly
software can sometimes speed up the computations considerably, the computational gain
is not always obvious upfront and for some advanced models the new developments may
not be suitable yet. In addition, the majority of the practical Bayesians still use BUGS-
related software. In this context, Lunn et al. [18] proposed to fit a hierarchical model in
two stages. The authors claim more model flexibility in this way, but advocate the use
of their procedure especially for its computational properties. In this paper we further
illustrate the use of the two-stage approach on a far more complex hierarchical data
structure of glaucoma patients. In addition, we extended the approach with an additional
sampling step to allow for the calculation of model selection and model evaluation criteria.
Our modeling approach is motivated by data from the Glaucoma Study conducted
by the Rotterdam Eye Hospital in the Netherlands. According to the World Health
Organization (WHO), glaucoma is one of the leading causes of irreversible blindness in
the world [14]. Adequate treatment may slow down the disease, possibly even halting
its progression. Evaluation of a longitudinal series of visual fields (VF), as measured by
standard automated perimetry (SAP), provides a way to detect early evidence of glaucoma
and to determine functional deterioration. However, due to the subjective nature of this
technique, SAP is prone to large variability. In order to measure the true progression of
the disease, this variability needs to be taken into account. The Glaucoma Study provides
a unique database with a long follow up time. Although methods may have existed to
model this type of data, the difficulties in extracting it from the device has made this type
of data rare and hence has prevented much research on the topic.
The response variable of interest are the sensitivity estimates which describe the level
of differential light sensitivity at different locations within each eye. The sensitivity esti-
mates are left-censored due to the limitation of the device. Models which take into account
2
this type of censoring, such as the Tobit model, have been described in the literature [28].
Our interest lies in modeling the latent, true values rather than the observed sensitivity
estimates for two reasons. Firstly, clinical interest lies in predicting the disease progression
rather than the observed sensitivity estimates. Secondly, using the latent scale allows us
to use a simpler model than when directly modeling the observed data. The hierarchical
structure of the data consists of 4 levels, namely, (1) the individual, (2) the eye (3) the
hemifield and (4) the location. There is a vast amount of literature that addresses hier-
archical mixed effects models, for both frequentist [29] and Bayesian [17, 21] approaches.
We model this complex data structure using a Bayesian hierarchical mixed effects model
with cross-classified random effects. Hence, we combine both spatial and time effects.
One of the difficulties in modeling VF data is the amount and type of measurement error
or variability in the sensitivity estimates. This may be due to measurable factors, such as
season, time of day and reliability indices, or unknown transient factors, such as fatigue,
lack of concentration, or delayed reaction time. Although their magnitudes may vary,
these factors affect all locations belonging to the same VF. We propose to model them
as Global Visit Effects (GVEs). Furthermore, there is an inverse relationship between
sensitivity and variability. For example, measurement error in the VFs increases with
damage, and hence low sensitivity estimates have high variability. Therefore, it is naive
to assume a constant variance over the wide range of sensitivity estimates. In this paper,
we relax this assumption in order to incorporate this relationship. A problem with high
dimensional data and complex data structures, is that it is sometimes difficult or even
impossible to model them with standard MCMC algorithms. Lunn et al. [18] proposed a
two-stage approach, which allowed us to simplify the problem while still benefiting from
the advantages of a full Bayesian model. However, one of the disadvantages of this ap-
proach, is that it is not possible to directly obtain the random effects estimates needed
for most model evaluations. We address this issue by extending the two-stage approach
to be able to determine these estimates.
Our aim is to model this complex data structure in order to obtain better estimates
of the true evolution of the sensitivity over time, so that treatment strategies can be
optimized to prevent further progression of VF loss. The structure of the paper is as
follows. In Section 2 we give further details on the motivating data set and introduce the
research questions that triggered our modeling approach(es). In Section 3 we describe the
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models used in the analysis. In the subsequent section we briefly review computational
aspects of the analysis. Model comparison is dealt with in Section 5. In Section 6 we
apply our models to the Glaucoma Study data. Section 7 contains a concluding discussion.
Further details regarding the modeling approach are provided in an appendix.
2 Motivating data set: the Glaucoma Study
2.1 Description of the project
The Glaucoma Study is a prospective cohort study conducted by the Rotterdam Eye
Hospital in the Netherlands. This is an ongoing study which began in 1998. Inclusion
criteria included glaucoma diagnosis and an age range of 18 to 85 years. In total, 139
patients, consisting of 80 (57.6%) men and 59 (42.4%) women, were recruited with a
mean follow-up of 10.5 years. Follow-up data were collected at approximately 6-monthly
intervals. All patients gave their written informed consent for participation. All research
procedures followed the tenets set forth in the Declaration of Helsinki. Furthermore, all
of the data that was used in this analysis has been made available online at http://rod-
rep.com.
Sensitivity estimates were measured at 52 test locations within each eye, or 26 test
locations within each hemifield (excluding two locations corresponding to the blind spot)
as shown in Figure 1. The VFs were tested using the Humphrey Field Analyzer with the
24-2, white-on-white test strategy using the Full Threshold algorithm. The light source
can be attenuated in the range from 1 to 10,000 times. On the decibel (dB) scale an
attenuation x is defined as s = 10 log10(x), or x = 10
s/10. The lowest sensitivity that
can be detected by this perimeter is 0 dB, although negative values could in fact occur if
it were not for the limitations of this device. The highest sensitivity that can be detected
is 50 dB, however few humans are capable of seeing a stimulus less than 40 dB, which
is 1/10,000 of the maximum intensity of the instrument (or 1 asb). Thus, for practical
purposes, the useful intensity range for white light testing is from 0 to 40 dB with a
background illumination of 31.5 asb. [1].
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Figure 1: Fundus photo of a left human eye with the 54 test locations for the VF test represented
by white dots.
2.2 Previous research
Parameters such as the mean deviation (MD) and visual field index (VFI) summarize
the 52 sensitivity estimates into single values which can be used by the clinicians when
optimizing treatment strategies. Longitudinal modeling of these VF summary parameters
has been done before [2, 4, 13, 15]. Modeling of individual test locations is potentially of
greater interest, because it provides additional information such as the spatial nature of
the fields which is otherwise lost in global parameters. In previous research, each location
was analyzed as an independent sample [5, 6, 20]. However, separate location-specific
regression models are not able to use any information from the data set as a whole.
Multilevel mixed-effects models provide a better fit to the data than separate regression
models by accounting for group effects and/or within-group correlation [29]. This was
shown in the context of global VF measurements by Pathak et al. [22].
In glaucoma, variability is presumably related to fatigue effects and response errors,
whereby sensitivity estimates decrease over time [3, 12]. Differences in fatigue effects,
between the inferior and superior hemifields within an eye have been demonstrated [12].
Furthermore, this effect may differ between the first and second eye at the same visit. The
number of false-negative answers have been shown to be higher in eyes with field loss. This
may be explained by an increased variability in sensitivity estimates typically found in such
eyes [3, 25]. A common approach to reduce measurement variability is to average multiple
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measurements. For example, random uncorrelated measurement errors that are present
in the point-wise sensitivity estimates are reduced when calculating summary parameters
such as the mean deviation (MD). Other errors, however, are spatially correlated and
affect the whole VF. One group of such errors are measurable factors, including season,
time of day and reliability indices, which have been evaluated before [13]. Although these
factors are statistically significant, they are rather small and hence only explain a small
part of the observed global variation in VFs.
The inverse relationship between variability and sensitivity has been described in the
literature. Henson et al. (2000) [10] found that this relationship is well represented by the
function log(SD) = A+B×sensitivity(dB), where A and B are 2.81 dB and -0.066 dB
respectively for normal eyes and 3.62 dB and -0.098 dB for glaucomatous eyes. Russell
et al. (2012) [25] showed that the distribution of residuals is relatively concentrated at
high VF sensitivities (26 to 36 dB) but stretches substantially as the sensitivity estimates
decrease to a level of 10 dB. Sensitivity estimates near 10 dB are associated with residuals
spanning almost the entire dynamic range of the instrument. This could be caused by a
loss of ganglion cells (due to glaucomatous damage), or relocation of the stimulus to the
peripheral visual field where there are fewer ganglion cells [27]. Zhu et al. (2014) [30] de-
scribe a method to detect change using an inferential statistical model which incorporates
the non-stationary variability using a mixture of Weibull distributions.
Although there is a wide range of literature which discusses these aspects, the majority
of previous work deals with the global indices or treats each point-wise estimate as an
independent sample. Furthermore, these aspects have been addressed separately. Hence,
it is clear that an approach which takes into account the complex structure of the data
and considers all of the aforementioned problems, is needed. We will address censoring,
the hierarchical structure, the global variation as well as the relationship between the
variability and sensitivity.
3 Statistical Models
Modeling the sensitivity estimates is beneficial for the evaluation of the progression of VF
loss. By incorporating biological effects into the model, we aimed to improve the model
fit and hence provide a better method for modeling this progression. This was done by
building the model up sequentially.
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3.1 Censoring
It is important to note that unseen sensitivity estimates are indicated on the VF print out
as < 0. They are smaller than zero because the instrument is unable to determine such
sensitivities. Thus a model which defines the relationship between time and the latent,
true sensitivity value is needed. The relationship between the observed y∗ and the latent,
true sensitivity value y is given by,
y∗ = y × I(y ≥ 0) + 0× I(y < 0).
3.2 Hierarchical Model
We propose using a Bayesian hierarchical mixed effects model [17, 21] to analyze the
glaucoma data. This model is able to take into account both the within subject and
between subject variability. Furthermore, we capitalized on the common features within
each eye by taking into account the correlation between measurements belonging to the
same eye. In addition, correlation of VF measurements within the inferior and superior
hemifields, separated by the horizontal raphe, was assumed to be higher than between
hemifields. Hence, the hierarchical structure of the data consists of 4 levels, namely, (1)
the individual, (2) the eye (3) the hemifield and (4) the location. Let β correspond to the
regression parameters and yearsit represent the time between measurement t and the first
measurement for each individual i, ranging from 0 to 10.5 years. The individual-specific
intercept and slope are represented by α, the eye-specific intercept and slope by γ, the
hemifield-specific intercept and slope by η, and the location-specific intercept and slope
by λ. We then have, for individual i = 1, . . . , N ; eye e = 1, 2; hemifield h = 1, 2; location
l = 1, . . . , 26 and timepoint t = 1, . . . , Ti,
Model 1:
yiehlt = β0 + β1yearsit + α0i + α1iyearsit + γ0ie + γ1ieyearsit + η0ieh + η1iehyearsit +
λ0iehl + λ1iehlyearsit + iehlt (1)
= µ
(1)
iehlt + iehlt,
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where
αi = (
α0i
α1i ) ∼ N(( 00 ) ,Σα =
(
Σα11 Σα12
Σα21 Σα22
)
);
γie = (
γ0ie
γ1ie ) ∼ N(( 00 ) ,Σγ = ( Σγ11 Σγ12Σγ21 Σγ22 ));
ηieh = (
η0ieh
η1ieh ) ∼ N(( 00 ),Ση = ( Ση11 Ση12Ση21 Ση22 ));
λiehl =
(
λ0iehl
λ1iehl
)
∼ N(( 00 ) ,Σλ = ( Σλ11 Σλ12Σλ21 Σλ22 )) and
iehlt ∼ N(0, σ2).
3.3 Visit Effect
Junoy Montolio et al. (2012) [13] explicitly modeled the global variations with known
factors such as season, time of day and reliability indices. However, we speculated that
other transient factors, such as fatigue, lack of concentration, or delayed reaction time
may play a more important role. Since all these (as well as possibly other) factors, affect
all locations belonging to the same VF, we propose to take them together and to call them,
as well as model them as the Global Visit Effects (GVEs). In this way, we can account
for both the known and the unknown factors. Hence, the GVE accounts for all factors
that affect all measurements of the same eye at each visit. To illustrate the importance
of these factors, we show in Figure 2 the VFs over time of one eye, where all locations
have a drastic decrease in sensitivity at around 1 year. From the longitudinal profiles, it
is evident that this decrease is caused by something that affected all VF measurements
of that visit, rather than by actual damage. To account for the visit-dependent offset at
all locations, or GVE, we included a parameter, φiet, in the model to capture the offset
at every visit j for each eye k within each individual i. This gives,
Model 2:
yiehlt = µ
(1)
iehlt + φiet + iehlt
= µ
(2)
iehlt + iehlt. (2)
From an initial exploratory analysis, we observed a number of spikes in the distribution
of the visit effects. To accommodate these spikes, we assumed a t-distribution for φiet.
The t-distribution allows greater flexibility in the distribution of random effects compared
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Figure 2: Retinal sensitivity estimates over time for each location of the visual field in the left
eye of a single glaucoma patient. A decrease in the sensitivity estimates can be seen in all
locations at around 1 year. The longitudinal profile of the MD values over time are shown on
the right. The visit-dependent decrease is also clear at around 1 year for the MD.
to the normal distribution, and can handle heavy tails in random effects distributions [16].
Hence, we let,
φiet ∼ t(0, σ2φ, 3),
where t(µ, σ2, df) denotes the generalized t-distribution with mean µ, scale parameter σ,
and df degrees of freedom.
3.4 Relationship between Variability and Sensitivity
There is an association between a decline in VF sensitivity and an increase in response
variability. However, values lower than 0 dB cannot be measured. This inherent censoring
process introduces a positive bias at low sensitivity estimates, which is made worse by
the increased variability for low sensitivity estimates. We assumed a linear relationship
between the expected values of the sensitivity estimates and the logarithm of the standard
deviation. However, since we were interested in modeling the latent sensitivity estimates,
we extrapolated this linear relationship for predicted sensitivity estimates below 10 dB.
This can be seen in Figure 3. In this exploratory analysis, we found that the relationship
was well represented by the function log(SD) = A + B × sensitivity(dB), where A
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and B are 2.60 dB and -0.06 dB respectively. We extended Model 2 to incorporate this
relationship such that,
Model 3:
yiehlt = µ
(2)
iehlt + iehlt,
and
log(σiehlt) = f{E(yiehlt)}
= β∗0 + β
∗
1µ
(2)
iehlt, (3)
where f is a linear function. A summary of all the parameters and their definitions
for all the models is shown in Table 1.
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Figure 3: Bubbleplot representing the mean logarithm of the standard deviation for different
predicted sensitivity estimates determined using linear regression for each location. The pre-
dicted values were subdivided into groups with width 5 dB. The empty bubbles correspond to
the hypothetical values, corresponding to the censored measurements, for the mean logarithm of
the standard deviation for the predicted sensitivity estimates after extrapolation. The bubbles
are scaled to the logarithm of the number of observations.
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Table 1: Summary of parameters included cumulatively in each of the models
Model Parameter Definition
Model 1 yiehlt Latent sensitivity estimate
β0 Population-averaged intercept
β1 Population-averaged slope
α0i Individual-specific intercept
α1i Individual-specific slope
γ0i Eye-specific intercept
γ1i Eye-specific slope
η0i Hemifield-specific intercept
η1i Hemifield-specific slope
λ0i Location-specific intercept
λ1i Location-specific slope
σ2 Variance
Model 2 φiet Global visit effect
σ2φ Global Visit Effect variance
Model 3 β∗0 Intercept in logarithm of the standard deviation
β∗1 Slope in logarithm of the standard deviation
4 Estimation Approach
4.1 One-stage approach
The Bayesian approach takes into account the uncertainty in all model parameters and
allows for prior information to be incorporated. Furthermore, MCMC algorithms allow
greater flexibility by relaxing the strong parametric assumptions commonly used in most
frequentist hierarchical models [17, 18]. The classical Bayesian approach is one-stage hi-
erarchical modeling, which has the advantage that subject-specific and overall parameters
are estimated simultaneously. However, for a (relatively) large data set, this approach can
be difficult or even impossible to implement for complex models with standard MCMC
software. In our case, we had a total of 45,005 parameters which needed to be esti-
mated. As a consequence, we were unable to achieve convergence in a realistic time frame
and experienced computer memory limitations when using WinBUGS or JAGS. For such
situations, a computationally more efficient method is needed.
4.2 Two-stage approach
Lunn et al. [18] proposed two-stage Bayesian hierarchical modeling. The glaucoma data
also exhibit an hierarchical structure, but of a more complex nature. Figure 4 illustrates
the hierarchical structure of the glaucoma data, as well as the cross-classified random
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effects, divided into two stages. The two-stage approach allowed us to simplify the problem
by splitting hierarchical models with M levels at level m*. Independent parameters of
interest at level m* are obtained in stage 1 and used as proposal distributions for those
parameters in stage 2. Lunn et al. illustrated this method using models with two and
three levels. We applied this to a more complex model with four levels. In our case, we
split the levels at the individual level, treating each individual as their own sample. These
individuals were then analyzed independently before combining them to obtain population
level estimates.
Figure 4: Illustration of the hierarchical structure of the data divided into the first and second
stages as done in the two-stage approach.
4.2.1 First stage
In the first stage, we analyzed each individual separately. Without loss of generality, we
only show this for Model 3. This becomes:
yiehlt = α0i + α1iyearsit + γ0ie + γ1ieyearsit + η0ieh + η1iehyearsit +
λ0iehl + λ1iehlyearsit + φiet + iehlt, (4)
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where
γie = (
γ0ie
γ1ie ) ∼ N(( 00 ) ,Σγi = ( Σγ11i Σγ12iΣγ21i Σγ22i ));
ηieh = (
η0ieh
η1ieh ) ∼ N(( 00 ),Σηi = ( Ση11i Ση12iΣη21i Ση22i ));
λiehl =
(
λ0iehl
λ1iehl
)
∼ N(( 00 ) ,Σλi = ( Σλ11i Σλ12iΣλ21i Σλ22i ));
φiet ∼ t(0, σ2φi, 3) and
iehlt ∼ N(0, σ2iehlt),
and
log(σiehlt) = β
∗
0i + β
∗
1iµ
(2)
iehlt.
One important detail about the two-stage approach is that it allows the individual
variances to differ, i.e. Σγi, Σηi, Σλi and σ
2
φi, but also σiehlt since the regression coefficients
are now allowed to depend on the subject. This is in contrast to the one-stage model
which requires the variances to be the same, i.e. Σγ , Ση, Σλ and σ
2
φ. Hence, the two-
stage approach is more flexible, as it can account for these differences if they are present
in the data. In the Bayesian procedure prior distributions need to be assumed for all
parameters. Explicit expressions for the priors are given in the Appendix. In order to
prevent the second-stage sampler from becoming stuck near local posterior modes, large
independent samples are needed from this first stage [18]. To achieve this, we ran 200,000
iterations with a burn-in of 150,000 and thinning of 10, resulting in 138 samples of 5,000
iterations each for each parameter.
4.2.2 Second stage
In the first stage, αi and β
∗
i were treated as fixed effects. These parameters need to
be combined in the second stage to obtain the population-averaged effects, β and β∗.
We denote them as θi. In the case of a meta analysis, the random effects in the first
stage, which we denote as Li, may not be of direct interest. Hence, these terms can
be treated as nuisance parameters as done by Lunn et al. [18]. However, for clinical
applications such as ours, these may be important. In order to avoid further computational
problems, we took only the covariance matrices of the random effects in the first stage
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to the second stage, which allowed us to re-estimate the random effects in an additional
step. Since each of the elements in the matrices were treated as separate parameters
in the second stage, Cholesky decomposition of the covariance matrices of the random
effects, Σγi , Σηi and Σλi respectively, was used. More specifically, for each of the above
covariance matrices a full rank lower triangular matrix U with real and positive diagonal
entries was generated, ensuring that UUT is positive definite. We denote the Cholesky
decomposition factors for all of the covariance matrices by Ci. Hence, we let {θi, Ci}
represent parameters of interest from the first-stage. The samples of these parameters
were then used as proposal distributions within a Metropolis-Hastings step in the second-
stage to obtain {θ, C} = {θi, Ci, i = 1, . . . , N}. Three chains were initialized with different
starting values for all models determined from the first-stage samples. This was done
using the minimum value, the mean value and the maximum value for each parameter for
every individual. Upon convergence, we computed the posterior mean, median, standard
deviation with the equal tail 95% credible interval (CI) for all parameters of interest.
5 Model Evaluation
Standard approaches are applicable to the results from the first stage since this stage
represents a standard analysis. Hence, we evaluated the models at this stage for each
individual separately using posterior predictive checks (PPC), such as the χ2-test statistic.
A further comparison of the models was done after the second stage using the Deviance
Information Criterion (DIC) to determine the overall best model.
5.1 Posterior predictive check
We denote all parameters for individual i from the first stage, i.e. {θi, Ci, Li}, as ψi. Let
ψ1i , . . . , ψ
K
i be the converged Markov chain from p(ψi | yi). Furthermore the vector of
all responses for the ith individual is denoted by yi. The posterior predictive P-value
(PPP) for a discrepancy measure, D(yi | ψki ) is then calculated and replicated data y˜ki is
sampled fromp(yi | ψki ). D(y˜ki , ψki ) can then be computed for k in {1, . . . ,K}, and pD can
be estimated by,
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p¯D =
1
K
K∑
k=1
I[D(y˜ki , ψ
k
i ) ≤ D(yi, ψki )], (5)
Here, the Gelman χ2-test statistic [9] was used as the discrepancy measure to calculate
the PPC for each individual. This is defined as:
D(yi, ψ
k
i ) =
E∑
e=1
H∑
h=1
L∑
l=1
Ti∑
t=1
[yiehlt − E(yiehlt | ψki )]2
var(yiehlt | ψki )
, (6)
where E(yiehlt) is defined as µ
(2)
iehlt. A small value indicates a bad model fit. The above
predictive P-values can then be contrasted against a uniform distribution to evaluate
globally model fit for each individual. In general, if p¯D is smaller than 0.05 or larger than
0.95, then this is an indication that the model might not fit the data well. Note that this
procedure is, however, conservative because the data is used twice: one for model fit and
one for model evaluation, see e.g. [17].
5.2 Deviance Information Criterion
In a Bayesian framework, a common tool for model evaluation is the Deviance Information
Criterion (DIC) proposed by Spiegelhalter et al. (2002) [26]. The DIC is defined as:
DIC = D({θ¯, C¯}, L¯) + 2pD = D({θ, C}, L) + pD, (7)
where
pD = D({θ, C}L)−D({θ¯, C¯}, L¯).
In the definition of the DIC, we have the fixed effects parameters as well as the random
effects which are treated as nuisance parameters in the two-stage approach. One of the
disadvantages of the two-stage approach is not being able to directly obtain the random
effects estimates. Since most model evaluation methods, such as the Deviance Information
Criteria (DIC), require the random effect estimates for the computation, it is not clear
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how to evaluate models using this approach. To overcome this limitation, we propose
an extension of the two-stage approach, by including an additional step based on the
Method of Composition in combination with a Metropolis-within-Gibbs technique. More
specifically, for the calculation of the DIC we are required to obtain a sample of the
random effects from their posterior distribution p(Li | yi), which is written as:
p(Li | yi) =
∫
p(Li | yi,Ωi)p(Ωi | yi)dΩi, (8)
where Ωi = (β0, β1, β
∗
0 , β
∗
1 , α0i, α1i,Σγ ,Ση,Σλ, σ
2
φ) is the vector of all parameters of
main interest; Ω˜i represents the sampled values from the second stage. Identity (8) sug-
gests that we can use the following simulation scheme. This is a sampling algorithm based
on the Method of Composition in combination with a Metropolis-within-Gibbs technique,
which is applied to each individual. For the ith individual the computations are done as
follows:
Step 1: For iteration k, let the parameters estimated in the second stage of the two-
stage approach be denoted by Ω˜
(k)
i .
Step 2: Given Ω˜
(k)
i , we sample:
γ0ie, γ1ie, η0ieh, η1ieh, λ0iehl, λ1iehl and φiet,
which we denote as L
(k)
i . This is done using the Metropolis-within-Gibbs technique.
Thus, for each sequence of generated parameters from the second stage, we apply MCMC
sampling to obtain these estimates:
Step 2A: Initial values are determined using an optimization routine.
Step 2B: A random walk Metropolis Hastings algorithm is used for each of the levels.
This is done iteratively, to take into account the correlation between the levels.
Step 3: After an inital burn-in, we save the last estimate for each parameter in L
(k)
i .
Step 4: This is repeated for K iterations, resulting in:
L
(1)
i , L
(2)
i , . . . , L
(K)
i
Hence, in combination with the results from the second stage, we have now obtained
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all the parameter estimates which are needed to compute the DIC.
6 Application to the Glaucoma study
For this analysis we included both eyes from the 139 individuals belonging to the Glaucoma
study. After excluding VFs with unknown reliability as indicated by the instrument, 138
individuals and 276 eyes remained. This included 4,758 VFs, resulting in a data set
consisting of 14,352 VFs and 247,520 location-specific sensitivity estimates. All analyses
were done taking into account censoring, and hence using the latent sensitivity values,
yiehlt.
6.1 Results
The two-stage approach is advantageous, as it allows us to do exploratory analyses at the
individual level in order to simplify the model before combining the samples in the second
stage. In order to compare the models, we can evaluate the outcome of the PPC using
graphical output. The PPP-values denoted by p¯D were computed for every individual.
Figure 5 shows the ordered PPP-values for each of the models. Model 1 has a mean
p¯D = 0.30, Model 2 a mean p¯D = 0.30 and Model 3 a mean p¯D = 0.50. From this, it
appears that Model 3 has the best fit. This approach gives a good indication of whether
the models fit the data, specifically for each individual.
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
4
0.
8
Ordinates of the Uniform quantiles
O
rd
er
ed
 P
PP
−v
a
lu
es Model 1
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
4
0.
8
Ordinates of the Uniform quantiles
O
rd
er
ed
 P
PP
−v
a
lu
es Model 2
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
4
0.
8
Ordinates of the Uniform quantiles
O
rd
er
ed
 P
PP
−v
a
lu
es Model 3
Figure 5: Posterior predictive check for each of the models across all individuals
An example of the model fits for 1 location is shown in Figure 6. The posterior
summary statistics from the second stage are listed in Table 2 for each of the models. A
difference in DIC of more than 10 indicates that the model with the lowest DIC has a
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better fit. Using the DIC to compare the models, Model 2 (DIC=−9.045e+07) performed
better than Model 1 (DIC = −8.827e+07), with Model 3 (DIC = −1.792e+26) performing
the best overall. Using the results from Model 3, the population intercept (β0) was 19.82
dB with an average slope (β1) of -0.31 dB per year. The intercept (β
∗
0) and slope (β
∗
1)
for the logarithm of the standard deviation was 2.82 dB and -0.08 dB respectively. This
corresponds to the 2.60 dB and -0.06 dB which was found in the exploratory analysis
shown in Figure 3.
Figure 6: Scatter plot representing the retinal sensitivity estimates over time for 1 location of
the VF. The lines represent the model fits for each of the 3 models
Table 2: Posterior summary statistics for the three models using the two-stage approach
Model 1 2 3
Parameter mean sd 95% CI mean sd 95% CI mean sd 95% CI
β0 18.95 0.72 (17.53 ; 20.36) 20.42 0.73 (18.95 ; 21.84) 19.89 0.77 (18.36 ; 21.37)
β1 -0.22 0.0 (-0.33 ; -0.13) -0.21 0.05 (-0.31 ; -0.11) -0.31 0.05 (-0.41 ; 0.20)
β∗0 2.82 0.06 (2.70 ; 2.95)
β∗1 -0.08 0.08 (-0.08 ; -0.07)
σ2 13.42 0.66 (12.17 ; 14.75) 11.51 0.56 (10.45 ; 12.68)
σ2φ 0.62 0.05 (0.52 ; 0.73) 1.87 0.04 (1.81 ; 1.96)
DIC −8.827e+07 −9.045e+07 −1.792e+26
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6.2 Clinical Implications
With the GVE, we account for those factors, as well as those which can not be measured
such as fatigue and delayed reaction time. Including the GVE showed a significant im-
provement in the model fit. Hence, by taking into account the GVE we were able to take
into account a large part of the variability and obtain better estimates of the true rate
of progression. By including the relationship between variability and sensitivity shows a
further improvement in the model fit. The function which describes this relationship was
consistent to that found by Henson et al [10], however it was not shown previously how
to include this relationship in a model, or whether including it would improve the model
fit. By including both of these aspects, we were able to improve the estimation of the
true underlying progression and determine the real evolution of the sensitivity over time.
Hence, these improved estimates could aid clinicians in optimizing treatment strategies.
7 Discussion
In this paper, we proposed a method to model point-wise VFs taking into account the
complexity of psychophysical testing of visual function in glaucoma. The model is advan-
tageous in dealing with the high measurement variability, and could be extended for the
prediction of future VFs. Although it was possible to use the one-stage approach with
simplied versions of the model or with smaller datasets, it was not possible to perform
these analysis on the full data with a complex model as it was with the two-stage ap-
proach. The two-stage approach can be implemented in standard MCMC software. The
relevant computations for the first-stage can be carried out in JAGS [23], WinBUGS or
OpenBUGS [19] software and the second-stage using OpenBUGS software [18]. However,
for the second stage an add-on program is needed. For more details on setting up Open-
BUGS for performing the two-stage analyses, we refer to [18]. More information regarding
the computations done in this paper can be obtained by emailing the first author. These
computations can be easily tuned to adapt to other data sets by any practitioner.
The two-stage method is advantageous as it allows us to do exploratory analysis at an
individual level. Hence, we are able to simplify and improve the model before combining it
at a population level. Limited simulations showed that the one- and two-stage approaches
gave similar results if the variances were the same for all individuals. The two-stage
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approach assumes a more flexible method. However, there is the additional difficulty in
constraining the parameters across individuals. One disadvantage of this approach is that
it does not provide the required components to evaluate the fit and predictive ability of
the model using the Deviance Information Criterion (DIC). In order to calculate the DIC
and compare different competing models for our data fitted using the two-stage approach,
we suggested a Monte Carlo scheme based on a Metropolis-within-Gibbs algorithm.
Other issues, which we see as future research directions, is to look at the optimal choice
of the level where the data should be split. Extensions include exploiting the spatial nature
of the data and capitalizing on the specific spatial organization of the nerve fibres in the
eye [7].
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A Appendix
A.1 One Stage Approach
A.1.1 Full Model
yiehlt = β0 + β1yearsit + α0i + α1iyearsit + γ0ie + γ1ieyearsit +
η0ieh + η1iehyearsit + λ0iehl + λ1iehlyearsij + φiet + iehlt (A.1)
where iehlt ∼ N(0, σ2iehlt) and log(σiehlt) = β∗0 + β∗1µ∗iehlt.
A.1.2 Priors
In the Bayesian procedure prior distributions need to be stipulated for all parameters.
When no prior information is available then the prior distribution should reflect this. In
this case a vague prior is a natural choice.
βb ∼ N(0, 108) for b = 0, 1;
β∗q ∼ N(0, 108) for q = 0, 1
αi = (
α0i
α1i ) ∼ N(( 00 ) ,Σα =
(
Σα11 Σα12
Σα21 Σα22
)
);
γie = (
γ0ie
γ1ie ) ∼ N(( 00 ) ,Σγ = ( Σγ11 Σγ12Σγ21 Σγ22 ));
ηieh = (
η0ieh
η1ieh ) ∼ N(( 00 ),Ση = ( Ση11 Ση12Ση21 Ση22 ));
λiehl =
(
λ0iehl
λ1iehl
)
∼ N(( 00 ) ,Σλ = ( Σλ11 Σλ12Σλ21 Σλ22 ));
φiet ∼ t(0, σ2φ, 3) and
iehlt ∼ N(0, σ2).
The variance was given a vague inverse gamma prior. The covariance matrices of the
random effects, i.e. Σγ , Ση and Σλ, were given a vague inverse Wishart distribution with
degrees of freedom equal to the number of dimensions and small diagonal values for the
scale matrix.
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A.2 Two Stage Approach
A.2.1 Full Model
yiehlt = β0 + β1yearsit + α0i + α1iyearsit + γ0ie + γ1ieyearsit +
η0ieh + η1iehyearsit + λ0iehl + λ1iehlyearsit + φiet + iehlt (A.2)
where iehlt ∼ N(0, σ2iehlt) and log(σiehlt) = β∗0 + β∗1µ∗iehlt.
A.2.2 Priors
φiet ∼ t(0, σ2φi, 3);σ2φi ∼ N(σ2φ,Σφ)
αgi ∼ N(0, 108) for g = 0, 1;
γie = (
γ0ie
γ1ie ) ∼ N(( 00 ) ,Σγi = ( Σγ11i Σγ12iΣγ21i Σγ22i ));
ηieh = (
η0ieh
η1ieh ) ∼ N(( 00 ),Σηi = ( Ση11i Ση12iΣη21i Ση22i ));
λiehl =
(
λ0iehl
λ1iehl
)
∼ N(( 00 ) ,Σλi = ( Σλ11i Σλ12iΣλ21i Σλ22i )) and
iehlt ∼ N(0, σ2iehlt).
Using Cholesky decompostion, Σγi , Σηi and Σλi become,
Crγi ∼ N(Crγ , 108) for r = 1, 2, 3
Crηi ∼ N(Crη, 108) for r = 1, 2, 3
Crλi ∼ N(Crλ, 108) for r = 1, 2, 3
A.2.3 First Stage Model
yiehlt = α0i + α1iyearsit + γ0ie + γ1ieyearsit + η0ieh + η1iehyearsit +
λ0iehl + λ1iehlyearsit + φiet + iehlt (A.3)
where iehlt ∼ N(0, σ2iehlt) and log(σiehlt) = β∗0i + β∗1iµ∗iehlt.
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A.2.4 First Stage Priors
β∗qi ∼ N(0, 108) for q = 0, 1
αgi ∼ N(0, 108) for g = 0, 1
φiet ∼ t(0, σ2φi , 3)
γie = (γ0ie, γ1ie)
T ∼ N2((0, 0)T ,Σγi)
ηieh = (η0ieh, η1ieh)
T ∼ N2((0, 0)T ,Σηi)
λiehl = (λ0iehl, λ1iehl)
T ∼ N2((0, 0)T ,Σλi).
The variance was given a vague inverse gamma prior. The covariance matrices of the
random effects, i.e. Σγi , Σηi and Σλi , were given a vague inverse Wishart distribution
with degrees of freedom equal to the number of dimensions and small diagonal values for
the scale matrix.
A.2.5 Second Stage Priors
β∗qi ∼ N(β∗q , 108) for q = 0, 1
αi = (α0i, α1i)
T ∼ N2((β0, β1)T ,Σα)
σ2φi ∼ N(σ2φ,Σφ)
Crγi ∼ N(Crγ , 108) for r = 1, 2, 3
Crηi ∼ N(Crη, 108) for r = 1, 2, 3
Crλi ∼ N(Crλ, 108) for r = 1, 2, 3
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B Methods
Let,
β∗ = {(β∗0i, β∗1i), for i = 1, . . . , N}
α = {(α0i, α1i), for i = 1, . . . , N}
Cγ = {(C1γi , C2γi , C3γi), for i = 1, . . . , N}
Cη = {(C1ηi , C2ηi , ..., C3ηi), for i = 1, . . . , N}
Cλ = {(C1λi , C2λi , ..., C3λi), for i = 1, . . . , N}
Then, from Lunn et al. (2013), θ = parameters of interest: α, β∗, Cγ , Cη, Cλ
λ = nuisance parameters: φ, γ, η, λ
µ = mean of θ: β(1), β(2), C¯γ , C¯η, C¯λ
Σ = covariance matrix of θ: Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ
B.1 Full Model
The joint posterior distribution is given by,
p(β(1), β(2), C¯γ , C¯η, C¯λ,Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ , α, β
∗, Cγ , Cη, Cλ, φ, γ, η, λ|y)
∝ p(β(1))p(β(2))p(Cγ)p(Cη)p(Cλ)p(C¯γ)p(C¯η)p(C¯λ)p(Σβ(1))p(Σβ(2))p(ΣCγ )p(ΣCη)p(ΣCλ)×
N∏
i=1
{
p(yi|αi, β∗i , Cγi , Cηi , Cλi , φi, γi, ηi, λi)p(αi|β(1),Σβ(1)) p(β∗i |β(2),Σβ(2)) ×
p(Cγi |C¯γ ,ΣCγ )p(Cηi |C¯η,ΣCη)p(Cλi |C¯λ,ΣCλ)p(φ, γ, η, λ)
}
(B.1)
B.2 First Stage
We analyse all individuals independently from the joint posterior distribution of each
αi, β
∗
i , Cγi , Cηi , Cλi conditional on yi alone,
p(αi, β
∗
i , Cγi , Cηi , Cλi , φi, γi, ηi, λi|yi) ∝ p(yi|αi, β∗i , Cγi , Cηi , Cλi , φi, γi, ηi, λi)×
p(αi, β
∗
i , Cγi , Cηi , Cλi)p(φi, γi, ηi, λi) (B.2)
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B.3 Second Stage
From the distributions in (2.1) these are given by,
p(β(1), β(2), C¯γ , C¯η, C¯λ|Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ , α, β∗, Cγ , Cη, Cλ, φ, γ, η, λ, y)
∝ p(β(1), β(2), C¯γ , C¯η, C¯λ)
N∏
i=1
p(αi, β
∗
i , Cγi , Cηi , Cλi |β(1), β(2), C¯γ , C¯η, C¯λ,
Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ) (B.3)
p(Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ |β(1), β(2), C¯γ , C¯η, C¯λ, α, β∗, Cγ , Cη, Cλ, φ, γ, η, λ, y)
∝ p(Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ)
N∏
i=1
p(αi, β
∗
i , Cγi , Cηi , Cλi |β(1), β(2), C¯γ , C¯η, C¯λ,
Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ) (B.4)
p(αi, β
∗
i , Cγi , Cηi , Cλi , φi, γi, ηi, λi|β(1), β(2), C¯γ , C¯η, C¯λ,Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ , y)
∝ p(yi|αi, β∗i , Cγi , Cηi , Cλi , φi, γi, ηi, λi, φi, γi, ηi, λi)p(αi, β∗i , Cγi , Cηi , Cλi |β(1), β(2),
C¯γ , C¯η, C¯λ,Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ)p(φi, γi, ηi, λi)
i = 1, ..., N. (B.5)
The distributions from (B.3) and (B.4) are available in closed form and can hence we can
sample from them directly by using standard algorithms. For the distributions (B.5) we
use the distributions in (B.2) as the proposal distributions within a Metropolis-Hastings
step. For this, the target-to-proposal ratio can be simplified to,
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C(αi, β
∗
i , Cγi , Cηi , Cλi , φi, γi, ηi, λi)
=
p(yi|αi, β∗i , Cγi , Cηi , Cλi , φi, γi, ηi, λi)
p(yi|αi, β∗i , Cγi , Cηi , Cλi , φi, γi, ηi, λi
)×
p(αi, β
∗
i , Cγi , Cηi , Cλi |β(1), β(2), C¯γ , C¯η, C¯λ,Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ)p(φi, γi, ηi, λi)
p(αi, β∗i , Cγi , Cηi , Cλi)p(φi, γi, ηi, λi)
=
p(αi, β
∗
i , Cγi , Cηi , Cλi |β(1), β(2), C¯γ , C¯η, C¯λ,Σβ(1),Σβ(2),ΣCγ ,ΣCη ,ΣCλ)
p(αi, β∗i , Cγi , Cηi , Cλi)
(B.6)
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